Evidence map›Paper›PMID 35995893›Full record

ArticleWorld journal of microbiology & biotechnology2022

7,8-Dihydroxyflavone attenuates the virulence of Staphylococcus aureus by inhibiting alpha-hemolysin.

Nan Bian, Xiangqian Chen, Xinran Ren, Zishu Yu, Mengli Jin, Xiaoyu Chen, Chang Liu, Yanhe Luan, Lin Wei, Ying Chen and 8 more

Abstract read
PubMed Publisher
In one paragraph

Article in World journal of microbiology & biotechnology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.1field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. DisarmingPathogens (Basel, Switzerland) · 2025
    Review
  5. Inhibitory effect of Jingfang mixture on Staphylococcus aureus α-hemolysin.World journal of microbiology & biotechnology · 2024
    Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 3 institutions in 1 country.

Nan BianChangchun University of Chinese Medicine, Changchun, 130117, China.
Xiangqian ChenChangchun University of Chinese Medicine, Changchun, 130117, China.
Xinran RenSchool of Pharmaceutical Science, Jilin University, Changchun, 130021, China.
Zishu YuChangchun University of Chinese Medicine, Changchun, 130117, China.
Mengli JinChangchun University of Chinese Medicine, Changchun, 130117, China.
Xiaoyu ChenChangchun University of Chinese Medicine, Changchun, 130117, China.
Chang LiuChangchun University of Chinese Medicine, Changchun, 130117, China.
Yanhe LuanThe First Affiliated Hospital to Changchun University of Chinese Medicine, Changchun, 130021, China.
Lin WeiChangchun University of Chinese Medicine, Changchun, 130117, China.
Ying ChenThe First Affiliated Hospital to Changchun University of Chinese Medicine, Changchun, 130021, China.
Wu SongChangchun University of Chinese Medicine, Changchun, 130117, China.
Yicheng ZhaoChangchun University of Chinese Medicine, Changchun, 130117, China.
Bingmei WangChangchun University of Chinese Medicine, Changchun, 130117, China.
Tao JiangChangchun University of Chinese Medicine, Changchun, 130117, China.
Chi ZhangChangchun University of Chinese Medicine, Changchun, 130117, China.
Zunhua ShuThe Third Affiliated Hospital to Changchun University of Chinese Medicine, Changchun, 130118, China. shuzunhua@163.com.
Xin SuChangchun University of Chinese Medicine, Changchun, 130117, China. 183073147@qq.com.
Li WangChangchun University of Chinese Medicine, Changchun, 130117, China. liwang1006@126.com.ORCID http://orcid.org/0000-0001-9639-1058
Changchun University of Chinese Medicine · CNThe Affiliated Hospital to Changchun University of Chinese Medicine · CNJilin University · CN

Funding

Science and Technology Development Plan Project (2019) of Jilin Province Science and Technology Department 20190103080JH"Xinglin Scholar Project" of Changchun University of Chinese Medicine (2019) and "Thirteenth Five-Year Plan" of Science and Technology Project of Education Department of Jilin Province JJKH20200906KJ
6 · The paper itself

Abstract

Staphylococcus aureus (S. aureus), a Gram-positive bacteria, is an incurable cause of hospital and community-acquired infections. Inhibition bacterial virulence is a viable strategy against S. aureus infections based on the multiple virulence factors secreted by S. aureus. Alpha-hemolysin (Hla) plays a crucial role in bacteria virulence without affecting bacterial viability. Here, we identified that 7,8-Dihydroxyflavone (7,8-DHF), a natural compound, was able to decrease the expression of and did not affect the in vitro growth of S. aureus USA300 at a concentration of 32 μg/mL. It was verified by western blot and RT-qPCR that the natural compound could inhibit the transcription and translation of Hla. Further mechanism studies revealed that 7,8-DHF has a negative effect on transcriptional regulator agrA and RNAIII, preventing the upregulation of virulence gene. Cytotoxicity assays showed that 7,8-DHF did not produce significant cytotoxicity to A549 cells. Animal experiments showed that the combination of 7,8-DHF and vancomycin had a more significant therapeutic effect on S. aureus infection, reflecting the synergistic effect of 7,8-DHF with antibiotics. In conclusion, 7,8-DHF was able to target Hla to protect host cells from hemolysis while limiting the development of bacterial resistance.

Indexed as

Bacterial ToxinsFlavonesStaphylococcal InfectionsStaphylococcus aureusA549 CellsAnimalsAnti-Bacterial AgentsHemolysin ProteinsHumansVirulenceVirulence Factors6,7-dihydroxyflavoneAnti-Bacterial AgentsBacterial ToxinsFlavonesHemolysin ProteinsVirulence Factors7,8-DihydroxyflavoneMice pneumonia modelStaphylococcus aureusα-hemolysin

Identifiers

PMID35995893
OpenAlexW4293250676

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.